Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Vadillo

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
European Journal of Cancer (Oxford, England : 1990)|June 1, 1997
Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-IIA Jungwirth, J Pinski, G Galvan, et al.
European Journal of Endocrinology|September 1, 1994
Inhibition of luteinizing hormone, follicle-stimulating hormone and sex-steroid levels in men and women with a potent antagonist analog of luteinizing hormone-releasing hormone, Cetrorelix (SB-75)D Gonzalez-Barcena, M Vadillo Buenfil, E Garcia Procel, et al.
Urology|February 1, 1995
Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cordD Gonzalez-Barcena, M Vadillo-Buenfil, A Cortez-Morales, et al.
The Prostate|January 1, 1994
Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancerD Gonzalez-Barcena, M Vadillo-Buenfil, F Gomez-Orta, et al.
Gastroenterologia Y Hepatologia|December 11, 1999
[Peritoneal tuberculosis with elevated CA-125 in serum and ascitic fluid]J Saavedra López, D Cabello Melendo, A de Gispert Servitge, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|November 16, 2002
IFN-alpha as induction and maintenance treatment of patients newly diagnosed with Waldenström's macroglobulinemiaJ Vela-Ojeda, M A García-Ruiz Esparza, Y Padilla-González, et al.
Annals of Hematology|April 3, 2004
Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: prognostic significance of the dose of CD3(+) and CD4(+) lymphocytesJ Vela-Ojeda, M A García-Ruiz Esparza, E Reyes-Maldonado, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
European Journal of Cancer (Oxford, England : 1990)|June 1, 1997
Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-IIA Jungwirth, J Pinski, G Galvan, et al.
European Journal of Endocrinology|September 1, 1994
Inhibition of luteinizing hormone, follicle-stimulating hormone and sex-steroid levels in men and women with a potent antagonist analog of luteinizing hormone-releasing hormone, Cetrorelix (SB-75)D Gonzalez-Barcena, M Vadillo Buenfil, E Garcia Procel, et al.
Urology|February 1, 1995
Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cordD Gonzalez-Barcena, M Vadillo-Buenfil, A Cortez-Morales, et al.
The Prostate|January 1, 1994
Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancerD Gonzalez-Barcena, M Vadillo-Buenfil, F Gomez-Orta, et al.
Gastroenterologia Y Hepatologia|December 11, 1999
[Peritoneal tuberculosis with elevated CA-125 in serum and ascitic fluid]J Saavedra López, D Cabello Melendo, A de Gispert Servitge, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|November 16, 2002
IFN-alpha as induction and maintenance treatment of patients newly diagnosed with Waldenström's macroglobulinemiaJ Vela-Ojeda, M A García-Ruiz Esparza, Y Padilla-González, et al.
Annals of Hematology|April 3, 2004
Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: prognostic significance of the dose of CD3(+) and CD4(+) lymphocytesJ Vela-Ojeda, M A García-Ruiz Esparza, E Reyes-Maldonado, et al.
Pageof 6